

Pharmacy

Attention: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

In this Newsletter:

Attention: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Contact Details

1-800-343-9000 emednyalert@csc.com Attention: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

">Effective June 20, 2013, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

• Pulmicort Respules and Zovirax ointment will be added to the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (*Updated 5/30/13*):

- Accolate
- Adderall & Adderall XR

- Alphagan P 0.15%
- Astelin
- Bactroban cream
- Carbatrol
- Catapres TTS
- Combivir
- Diastat
- Diovan HCT
- Duetact
- Epivir
- Felbatol
- Gabitril 2mg, 4mg
- Gris-PEG
- Kadian
- Lovenox
- Maxalt MLT
- Nasacort AQ
- Pulmicort Respules
- Sanctura XR
- Singulair granules
- Symbyax
- Tegretol suspension
- Tegretol XR
- Tobradex
- Tricor
- Trileptal suspension
- Valtrex
- Vancocin
- Ziagen tablet
- Zovirax ointment

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.

If you are having problems viewing content within this newsletter, please email emednyalert@csc.com for further assistance.

^{*}List is subject to change

Message Sent 05/31/2013

| The Department has attempted to ensure that | the information contained in these | e notifications is as accurate as possible. |
|--|-------------------------------------|---|
| However, no e-mail transmittals or materials | provided are intended to constitute | e legal or medical advice. |